Literature DB >> 22236282

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

C B Carroll1, M-L Zeissler, C O Hanemann, J P Zajicek.   

Abstract

AIMS: Δ⁹-tetrahydrocannabinol (Δ⁹-THC) is neuroprotective in models of Parkinson's disease (PD). Although CB1 receptors are increased within the basal ganglia of PD patients and animal models, current evidence suggests a role for CB1 receptor-independent mechanisms. Here, we utilized a human neuronal cell culture PD model to further investigate the protective properties of Δ⁹-THC.
METHODS: Differentiated SH-SY5Y neuroblastoma cells were exposed to PD-relevant toxins: 1-methyl-4-phenylpyridinium (MPP+), lactacystin and paraquat. Changes in CB1 receptor level were determined by quantitative polymerase chain reaction and Western blotting. Cannabinoids and modulatory compounds were co-administered with toxins for 48 h and the effects on cell death, viability, apoptosis and oxidative stress assessed.
RESULTS: We found CB1 receptor up-regulation in response to MPP+, lactacystin and paraquat and a protective effect of Δ⁹-THC against all three toxins. This neuroprotective effect was not reproduced by the CB1 receptor agonist WIN55,212-2 or blocked by the CB1 antagonist AM251. Furthermore, the antioxidants α-tocopherol and butylhydroxytoluene as well as the antioxidant cannabinoids, nabilone and cannabidiol were unable to elicit the same neuroprotection as Δ⁹-THC. However, the peroxisome proliferator-activated receptor-gamma (PPARγ) antagonist T0070907 dose-dependently blocked the neuroprotective, antioxidant and anti-apoptotic effects of Δ⁹-THC, while the PPARγ agonist pioglitazone resulted in protection from MPP+-induced neurotoxicity. Furthermore, Δ⁹-THC increased PPARγ expression in MPP+-treated SH-SY5Y cells, another indicator of PPARγ activation.
CONCLUSIONS: We have demonstrated up-regulation of the CB1 receptor in direct response to neuronal injury in a human PD cell culture model, and a direct neuronal protective effect of Δ⁹-THC that may be mediated through PPARγ activation.
© 2011 The Authors. Neuropathology and Applied Neurobiology © 2011 British Neuropathological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236282     DOI: 10.1111/j.1365-2990.2011.01248.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  31 in total

Review 1.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

Review 2.  Therapy for Parkinson's disease: what is in the pipeline?

Authors:  Fabrizio Stocchi
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  The influence of cannabinoids on generic traits of neurodegeneration.

Authors:  S G Fagan; V A Campbell
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 4.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

Review 5.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

Review 6.  Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.

Authors:  Gareth Pryce; Dieter R Riddall; David L Selwood; Gavin Giovannoni; David Baker
Journal:  J Neuroimmune Pharmacol       Date:  2014-12-24       Impact factor: 4.147

Review 7.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 8.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 9.  The endocannabinoid system in normal and pathological brain ageing.

Authors:  Andras Bilkei-Gorzo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

10.  Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins.

Authors:  Patrícia Schönhofen; Liana M de Medeiros; Ivi Juliana Bristot; Fernanda M Lopes; Marco A De Bastiani; Flávio Kapczinski; José Alexandre S Crippa; Mauro Antônio A Castro; Richard B Parsons; Fábio Klamt
Journal:  Mol Neurobiol       Date:  2014-08-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.